Drug Trial Radar · NCT05444257
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
822
Actual
Start
Nov 8, 2022
Primary completion
Oct 30, 2026
Study completion Oct 30, 2026
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Jul 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with cystic fibrosis.
Conditions
- Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVADrug
Fixed-dose combination tablets for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Baseline up to Week 148
Locations
195 sites in 23 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Banner University of Arizona Medical Center
Tucson, Arizona
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Miller Children's Hospital / Long Beach Memorial
Long Beach, California
Children's Hospital Los Angeles
Los Angeles, California
Kaiser Permanente
Oakland, California
University of California Davis Medical Center
Sacramento, California
University of California San Francisco, Lung Transplant Program
San Francisco, California
Children's Hospital of Colorado
Aurora, Colorado
National Jewish Health
Denver, Colorado
University of Florida, Shands Hospital
Gainesville, Florida
Joe DiMaggio Cystic Fibrosis & Pulmonary Center
Hollywood, Florida
University of Miami Miller School of Medicine
Miami, Florida
Central Florida Pulmonary Group,PA
Orlando, Florida
Nemours Children's Specialty Care
Pensacola, Florida
Johns Hopkins All Children's Hospital Outpatient Care Center
St. Petersburg, Florida
The Emory Clinic at Chantilly
Atlanta, Georgia
Augusta University
Augusta, Georgia
St. Luke's Cystic Fibrosis Center of Idaho
Boise, Idaho
Northwestern Memorial Hospital
Chicago, Illinois
Indiana University
Indianapolis, Indiana
Riley Hospital for Children at Indiana University Health
Indianapolis, Indiana
University of Kansas Medical Center
Kansas City, Kansas
University of Kentucky
Lexington, Kentucky
Tulane Medical Center
New Orleans, Louisiana
Maine Medical Partners
Portland, Maine
Massachusetts General Hospital Cystic Fibrosis Center Clinical Research Center
Boston, Massachusetts
Boston Children's Hospital
Boston, Massachusetts
UMass Memorial Medical Center
Worcester, Massachusetts
Michigan Medicine
Ann Arbor, Michigan
Harper University Hospital
Detroit, Michigan
Spectrum Health Medical Group Adult Cystic Fibrosis Care Center
Grand Rapids, Michigan
University of Minnesota
Minneapolis, Minnesota
Childrens Hospital University of Missouri Health Sciences Center
Columbia, Missouri
The Children's Mercy Hospital
Kansas City, Missouri
Cardinal Glennon Children's Hospital - St. Louis University
St Louis, Missouri
Washington University School of Medicine / St. Louis Children's Hospital
St Louis, Missouri
Billings Clinic
Billings, Montana
Nebraska Medical Center
Omaha, Nebraska
Dartmouth Hitchcock
Manchester, New Hampshire
Showing 40 of 195 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.